Go Symbol Lookup
Loading...

Europe Closes Lower; Fed in Focus

This Bank May See Dividend Hike Next Year: Stock Picker

 Text Size  
Published: Thursday, 7 Apr 2011 | 10:39 AM ET
By: | CNBC.com Writer

There’s still value in the stock market even if shares have rallied nearly 100 percent since their March 2009 lows, said Jeff Layman, CIO of BKD Wealth Advisors.

Markets: Thrifty Thursday
Jeff Layman, BKD Wealth Advisors, and Bill Smead, Smead Capital Mgmt. discuss sectors and companies their watching today.

Layman’s picks include Intel , Teva Pharmaceuticals and JPMorgan .

“There’s a lot of macroeconomic support for [JPMorgan],” Layman told CNBC. “We think the dividend will be higher a year from now, and as long as the economy continues to heal, this company ought to produce earnings that are better than expected.”

In the meantime, Bill Smead, CEO and CIO of Smead Capital Management, said he likes companies that generate “high levels of free cash flow.”

“It appears even the U.S. government is going to quit stimulating and that interest rates are going to rise around the world,” he said. “So we like the pharmaceutical companies.”

Smead's Picks:

Mylan Lab

Bristol-Myers

Cabela’s

______________________________

Scorecard—What They Said:

  • Layman's Previous Appearance on CNBC (Oct. 26, 2010)
  • Smead's Previous Appearance on CNBC (Mar. 28, 2011)

______________________________

More Market Intelligence:

______________________________

CNBC Data Pages:

______________________________
CNBC Slideshows:

______________________________
Disclosures:

Smead owns shares of MYL, BMY and CAB in the Smead Value Fund.

No immediate information was available for Layman or his firm.

______________________________

Disclaimer

 Print
There’s still value in this market even if stocks have rallied nearly 100 percent since the March 2009 lows, said Jeff Layman, CIO of BKD Wealth Advisors.
  Price   Change %Change
BMY ---
CAB ---
INTC ---
JPM MLP ETN ---
MYL ---
TEVA ---

   
Comments

 

More Comments

 
 

Add Comments

 

Your Comments (Up to 1100 characters):

Remaining characters

Your comments have not been posted yet.

Please review your submission to make sure you are comfortable with your entry.

Your Comments:


                
            
            
        

Featured